Table 4.
Rate of concordance of recommendations according to different sections in the primary analysis and sensitivity analysis
| 2017 ACC/AHA guideline | 2018 ESC/ESH guideline | |||
|---|---|---|---|---|
| Reference recommendations, No | Concordance, No. (%) | Reference recommendations, No | Concordance, No. (%) | |
| Primary analysis | ||||
| Blood pressure measurementa | 1 | 1 (100) | 1 | 1 (100) |
| Diagnosis of hypertensionb | 5 | 1 (20.0) | 4 | 3 (75.0) |
| Investigations of patients with hypertensionc | 11 | 4 (36.3) | 10 | 4 (40.0) |
| Lifestyle modificationsd | 6 | 6 (100) | 6 | 6 (100) |
| Goal blood pressuree | 8 | 0 (0) | 7 | 0 (0) |
| Pharmacotherapy for patients with hypertension and no comorbidityf | 10 | 6 (60.0) | 10 | 6 (60.0) |
| Pharmacotherapy for patients with hypertension and comorbidityg | 18 | 12 (66.7) | 13 | 11 (84.6) |
| Sensitivity analysis excluding insufficient ratings | ||||
| Blood pressure measurementa | 1 | 1 (100) | 1 | 1 (100) |
| Diagnosis of hypertensionb | 5 | 2 (40.0) | 4 | 4 (100) |
| Investigations of patients with hypertensionc | 11 | 5 (45.4) | 10 | 4 (40.0) |
| Lifestyle modificationsd | 6 | 6 (100) | 6 | 6 (100) |
| Goal blood pressuree | 8 | 0 (0) | 7 | 0 (0) |
| Pharmacotherapy for patients with hypertension and no comorbidityf | 10 | 6 (60.0) | 10 | 6 (60.0) |
| Pharmacotherapy for patients with hypertension and comorbidityg | 14 | 13 (92.9) | 11 | 11 (100) |
ACC: American College of Cardiology; AHA: American Heart Association; ESC: European Society of Cardiology; ESH: European Society of Hypertension
aACC-1; ESC-1
bACC-2 to ACC-6; ESC-2 to ESC-5
cACC-7 to ACC-17; ESC-6 to ESC-15
dACC-18 to ACC-23; ESC-16 to ESC-21
eACC-24 to ACC-31; ESC-22 to ESC-28
fACC-32 to ACC-41; ESC-29 to ESC-38
gACC-42 to ACC-59; ESC-38 to ESC-51